Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
EFFERVESCENT FORMULATIONS COMPRISING CEFACLOR AND CLAVULANIC ACID
Document Type and Number:
WIPO Patent Application WO/2011/093823
Kind Code:
A2
Abstract:
Present invention relates to pharmaceutical formulations in effervescent form comprising cefaclor and clavulanic acid.

Inventors:
BILGIC MAHMUT (TR)
Application Number:
PCT/TR2011/000027
Publication Date:
August 04, 2011
Filing Date:
January 28, 2011
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
BILGIC MAHMUT (TR)
International Classes:
A61K9/00; A61K9/20; A61K31/43; A61K31/545; A61P11/00; A61P13/00; A61P31/00
Domestic Patent References:
WO1995028927A11995-11-02
WO1997009042A11997-03-13
WO1994016696A11994-08-04
Foreign References:
US3925372A1975-12-09
EP1269996A12003-01-02
Other References:
MARTIN M A ET AL: "INCREASE IN THE ACTIVITY OF THIRD-GENERATION CEPHALOSPORINS IN COMBINATION WITH CLAVULANIC ACID AND SULBACTAM AGAINST BACTEROIDES-FRAGILIS", MEDICAL LABORATORY SCIENCES, ACADEMIC PRESS, LONDON, GB, vol. 47, no. 3, 1 January 1990 (1990-01-01), pages 163-167, XP008133356, ISSN: 0308-3616
Attorney, Agent or Firm:
KOSE, Meliha, Merve (Merkezi Bagimsiz Bolum No: 2/13 Merter/Istanbul, Turkey, TR)
Download PDF:
Claims:
CLAIMS

1. A pharmaceutical composition formulated in effervescent form characterized in that said composition comprises 10-60% of cefaclor, 1-20% of the mixture of potasium clavulanate: humidity absorbing agent (1 : 1), 15-55% of effervescent couple and 1-15% of at least one pharmaceutically acceptable excipient by weight.

2. A pharmaceutical composition according to claim 1, wherein said composition comprises cefaclor and/or its solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystal and amorphous forms or in free form and/or as a combination thereof.

3. A pharmaceutical composition according to claim 2, wherein cefaclor is present in one of the forms of monohydrate, dihydrate, trihydrate and/or anhydrous.

4. A pharmaceutical composition according to claim 3, wherein cefaclor is present in monohydrate form.

5. A pharmaceutical composition according to claim 1, wherein said composition comprises clavulanic acid and/or its pharmaceutically acceptable solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, esters, free form, polymorphs, crystal forms, amorphous forms and/or combinations thereof.

6. A pharmaceutical composition according to claim 5, wherein wherein clavulanic acid used in the present invention is in the form of alkali metal salt.

7. A pharmaceutical composition according to claim 6, wherein clavulanic acid used in the present invention is in the form of potasium clavulanate salt.

8. A pharmaceutical composition according to claim 7, wherein potassium clavulanate is used together with a humidity absorbing agent.

9. A pharmaceutical composition according to claim 8, wherein syloid and/or microcrystalline cellulose is used as humidity absorbing agent.

10. A pharmaceutical composition according to claim 8, wherein potassium clavulanate: humidity absorbing agent ratio is 1 :1.

11. A pharmaceutical composition according to claim 1, wherein said composition is in the form of effervescent powder, granule or tablet.

12. A pharmaceutical composition according to claim 11, wherein said composition is in the form of effervescent tablet.

13. A pharmaceutical composition according to any one of the claims 1 to 12, wherein said composition is prepared as a single pharmaceutical composition comprising the mixture of two active agents.

14. A pharmaceutical composition according to claim 13, wherein the ratio of cefaclor to potassium clavulanate is in the range of 1 :0.01 to 1 :10.

15. A pharmaceutical composition according to claim 1, wherein amount of cefaclor in a single dose is approximately 50 to 1300 mg; amount of potassium clavulanate in a single dose is approximately 20 to 350 mg.

16. A pharmaceutical composition according to claim 1, wherein said formulation comprises as effervescent couple; an alkali component and an acid or an acidic salt which upon contact with aqueous solution gives off carbon dioxide.

17. A pharmaceutical composition according to claim 16, wherein alkali component that is used as effervescent base is selected from basic agents such as sodium hydrogen carbonate, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, potassium hydrogen carbonate, sodium glycine carbonate, lysine carbonate, arginine carbonate and calcium carbonate.

18. A pharmaceutical composition according to claim 17, wherein sodium hydrogen carbonate is used as alkali component.

19. A pharmaceutical composition according to claim 16, wherein effervescent acid is selected from a group comprising anhydrous organic or inorganic pharmaceutically acceptable acid; especially organic acids such as citric acid, tartaric acid, malic acid, fumaric acid, ascorbic acid, acetic acid, adipic acid, succinic acid, acetylsalicylic acid and/or acidic salts such as sodium citrate, sodium acetate, sodium dihydrogen phosphate, sodium acid pyrophosphate and sodium acid sulphite.

20. A pharmaceutical composition according to claim 19, wherein citric acid is used as effervescent acid.

21. A pharmaceutical composition according to claim 1, wherein said composition comprises cefaclor, potassium clavulanate and effervescent couple and additionally at least one excipient which is selected from a group comprising pharmaceutically acceptable amounts of binder, lubricant, sweetener and/or taste regulator, diluents, disintegrant, flavoring agent, coloring agent, surfactant, anti-foaming agent, humectants, acidic agent, basic agent.

22. A pharmaceutical composition according to claim 21, wherein polyethylene glycol (PEG), potato starch, wheat starch, corn starch, microcrystalline cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, hypromellose and polyvinylpyrrolidone (povidone) are used as binder.

23. A pharmaceutical composition according to claim 22, wherein povidone is used as binder.

24. A pharmaceutical composition according to claim 21, wherein lubricant is selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, sodium benzoate.

25. A pharmaceutical composition according to claim 24, wherein PEG 6000 is used as lubricant.

26. A pharmaceutical composition according to claim 21, wherein sweetener and/or taste regulator is selected from a group of acesulfame, aspartame, dextrose, fructose, maltitol, saccharin, sucralose, sodium chloride, saccharin sodium, lactitol, maltose, sorbitol, sodium cyclamate, sucrose and xylitol or a combination thereof.

27. A pharmaceutical composition according to claim 26, wherein sodium chloride and/or sucralose is used as sweetener and/or taste regulator.

28. A pharmaceutical compositions according to claim 21, wherein flavoring agent is selected from a group comprising banana flavor, strawberry flavor, lemon flavor, orange flavor, peach flavor, vanilla flavor or similar natural fruits or might have the flavor of a natural herb.

29. A pharmaceutical composition according to claim 21, wherein coloring agent is selected from titanium dioxide pigments, indigo carmin, beta carotene and iron oxide pigments.

30. A pharmaceutical composition according to claim 29, wherein beta carotene is used as coloring agent.

31. A pharmaceutical composition according to claim 1, wherein said composition comprises cefaclor in an amount of 10-60%, the mixture of potasium clavulanate: humidity absorbing agent (1 : 1) in an amount of 1-20%, effervescent couple in an amount of 15- 55%, binder in an amount of 1-5 %, lubricant in an amount of 0.1-2 %, sweetener in an amount of 0.5-5 % by weight and at least one pharmaceutically acceptable excipient.

32. A method for preparation of a pharmaceutical composition according to any of the preceding claims, wherein said method comprises preparation of the formulation by spray granulation method.

33. A method according to claim 32, wherein said method comprises the steps of mixing effective amount of effervescent couple, sweetener and pharmaceutically acceptable excipients homogeneously, granulation of the mixture with a sufficient amount of water by spray granulation and drying them and preparation of the final mixture by adding cefaclor, potassium clavulanate: humidity absorbing agent (1 :1) mixture, lubricant and at least one pharmaceutically acceptable excipient to the granulate.

34. A pharmaceutical formulation according to claim 1, wherein said formulation is used for treatment of infectious diseases that are resistant to antibiotics.

35. Infectious diseases according to claim 34 are upper respiratory tract infections (acute otitis media, acute sinusitis, acute streptococcus tonsilo pharangitis), urinary tract infections, commonly acquired pneumonia and infections of skin and soft tissue.

Description:
EFFERVESCENT FORMULATIONS COMPRISING CEFACLOR AND CLAVULANIC

ACID

Present invention relates to pharmaceutical formulations in effervescent form comprising cefaclor and clavulanic acid. Background of the invention

Cefaclor is a semi-synthetic, wide spectrum, second generation cephalosporin antibiotic which is shown with Formula (I) and which is disclosed in US3925372 (A) for the first time by Eli Lilly.

Cefaclor, which is physically in white or slightly yellow and in the powder form, dissolve in water slightly but does not dissolve in methanol and methylene chloride. The product sold in the market under the tradename CECLOR ® is present in capsule and suspension forms.

Cefaclor is used for treatment of infections caused by gram positive microorganisms; staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus pneumonia, Streptococcus pyogenes (group A streptococci), gram negative microorganisms; Haemophilus parainfluenzea, Haemophilus influenzae, Moraxella (Branhamella) catarrhalis, Escherichia coli, Klebsiella pneumonia, respiratory tract infections caused by Proteus mirabilisin such as (pneumonia, bronchitis, acute inflammations of chronic bronchitis, pharangitis, tonsilitis), middle-ear infections, sinusitis, skin and soft tissue infections and urinary tract infections (cystitis and pyelonephritis) Clavulanic acid that is shown with Formula II is a beta lactamase inhibitor:

Clavulanic acid and its derivatives (such as its salts like potassium clavulanate) are known as beta lactamase inhibitors that inhibit the activity of beta lactamase enzymes that is produced by the bacteria.

In state of the art, there are several studies disclosing combined use of beta lactam antibiotics and beta lactamase enzyme inhibitors for the prevention of antibiotic resistance. In the last years, the resistant bacteria is encompassed into the activity spectrum by developing combined penicilin preparates comprising combination of beta lactamase inhibitors such as clavulanic acid, sulbactam and tazobactam and penicilin derivatives like amoxicillin, ticarcillin, piperacillin.

For example, patent applications numbered W095/28927 and EP 1269996 respectively disclose use of amoxicillin and potassium clavulanate in combined form for treatment of bacterial infection and tablet formulations for this combination. WO97/09042 describes tablet formulations comprising amoxycillin and clavulanic acid in an amount in the ratio of 12: 1 to 20: 1 preferably in the ratio of 14: 1.

In the patent application numbered in W094/ 16696, it is disclosed that the use of the combination of beta lactam antibiotics like penicilin or cephalosporin and clavulanic acid for decreasing the enhanced resistance to beta-lactams by increasing the antibacterial activity and the dosage forms comprising these agents.

However, it is known that there are some adverse effects of penicilin antibiotics and their combination products, such as; diarrhea, oversensitiveness, nausea, neurotoxicity and especially serious allergic reactions.

Furthermore, at present state of the art, in the formulations applied orally clavulanic acid is usually found in a pharmaceutically acceptable salt form especially in the form of potassium clavulanate.

However, potassium clavulanate has an extremely hygroscopic nature and is sensitive to moisture therefore it is very difficult to formulate this compound. Therefore during its manufacture and use it should be kept away from water and mediums containing water otherwise degradation of the compound may take place. Its water sensitive nature and the fact that it is prone to hydrolysis decreases the stability of the formulations comprising clavulanate and leads to restrictions in these formulations. Clavulanic acid and beta lactam formulations known in the state of the art are in tablet, suspension and capsule forms (Augmentin®, Augmentin-Duo®). Commercially available Augmentin® is a film tablet formulation comprising clavulanic acid. Said tablet disperses in water at 37 °C in a relatively long time, e.g. 10- 15 minutes. In these dosage forms where large amounts of antibiotic are used, they become bigger in size when formulated with the excipients and this affects the ease of use negatively. Alternatively, the use of reliable and user-friendly effervescent forms is suggested.

In the prior art, although formulations comprising the combination of beta lactam antibiotic and beta lactamase inhibitor that is proposed for preventing the antibiotic resistance lead to fewer adverse effects, they have some stability and dissolution problems. For example, an antibiotic of cephalosporin group like cefaclor can not dissolve completely upon releasing the drug into the water since it has a hydrophobic character and it has solubility and wettability problems upon contact with water. This in turn causes a decrease in the absorption and bioavailability of the active agents present in the formulation. Moreover, the potasium clavulanate, which is the second active agent in the formulation, loses its activity by disintegrating in an aqueous medium due to its sensitivity to moisture and hydrolysing easily. In this case, formulations having low stability and short shelf-life are obtained.

As is seen, new approaches are needed for obtaining the drug formulations comprising antibiotic and beta-lactamase inhibitor, which have long shelf-life and high stability, minimum adverse effect and are used for the treatment of the resistant bacterial infections.

The inventors have surprisingly found that the problems in the prior art can be solved by the effervescent formulations that are prepared in accordance with the present invention.

Description of the Invention

The present invention is related to effervescent formulations comprising cefaclor and clavulanic acid and process for the preparation of these formulations. Surprisingly, it was seen that effervescent forms formulated with the formulations comprising 10-60% of cefaclor, 1 -20% of the mixture of potasium clavulanate: humidity absorbing agent (1 : 1), 15-55 % of effervescent couple and 1-15% of at least one pharmaceutically acceptable excipient by weight are quite stable and have long shelf-life and minimized adverse effects.

Accordingly, the present invention is related to the effervescent formulations comprising 10-60% of cefaclor, 1 -20% of the mixture of potasium clavulanate: humidity absorbing agent (1 : 1 ), 15-55 % of effervescent couple and 1-15% of at least one pharmaceutically acceptable excipient by weight. "Effervescent formulations" term used in the text comprises effervescent tablets, effervescent granules and effervescent powders.

Effervescent formulations are more advantageous compared to the conventional forms due to the fact that they quickly disperse. Effervescent formulations disperse quickly and simultaneously and they disperse the active agents into the aqueous medium. The fact that each dose is prepared prior to use, leads to consumption of the dose right after the preparation. This phenomenon prevents degradation of the active agents with water and it also prevents the necessity to use antimicrobial agent and hence makes the formulation suitable for pediatric use.

The pharmaceutical formulations can be in the form of powder or granule that can be compressed into tablets or filled into sachets. The effervescent formulations comprising cefaclor and potassium clavulanate is preferably compressed into tablets.

Cefaclor that can be used in the effervescent formulations in accordance with the present invention can be present in the form of its solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystal and amorphous forms or in free form; clavulanic acid can be present in the form of solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, esters, polymorphs, crystal and amorphous forms or in free form. ^

Cefaclor that is used in the present invention can be present in one of the forms of monohydrate, dihydrate, trihydrate and/or anhydrous. Preferably, it is used in the form of monohydrate.

According to the prior art, in the formulations administered orally, clavulanic acid is commonly used in the form of a pharmaceutically acceptable salt, especially potassium clavulanate.

Clavulanic acid used in the present invention is in the form of alkali metal salt, preferably potasium clavulanate.

Pharmaceutical formulations according to present invention may comprise effective amount of cefaclor, effective amount of potassium clavulanate, an effective effervescent couple, additionally at least one excipient selected from a group comprising pharmaceutically acceptable amount of binder, lubricant, sweeteners.

Accordingly, effervescent formulation in accordance with the present invention comprises a mixture of components which gives off carbon dioxide gas upon contact with water. This type of effervescent components are generally an acid or an acidic salt which may give off carbon dioxide gas upon contact with an alkali or alkali earth metal carbonate or hydrogen carbonate and an aqueous solution.

Effervescent acid that is used in the effervescent formulation according to the present invention is selected from a group comprising anhydrous organic or inorganic pharmaceutically acceptable acid; especially organic acids such as citric acid, tartaric acid, malic acid, fumaric acid, ascorbic acid, acetic acid, adipic acid, succinic acid, acetylsalicylic acid and/or acidic salts such as sodium citrate, sodium acetate, sodium dihydrogen phosphate, sodium acid pyrophosphate and sodium acid sulphite. Preferably, citric acid is used.

Alkali component that is used as effervescent base in the effervescent formulation according to the present invention can be selected from, but not limited with, sodium hydrogen carbonate, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, potassium hydrogen carbonate, sodium glycine carbonate, lysine carbonate, arginine carbonate and calcium carbonate. Preferably, sodium hydrogen carbonate is used.

Effervescent formulation in accordance with the present invention comprises cefaclor, potassium clavulanate, effervescent couple and additionally at least one excipient in pharmaceutically acceptable amounts wherein said at least one excipient is selected from a group comprising binder, lubricant, sweetener and/or taste regulator, diluents, disintegrant, flavoring agent, coloring agent, surfactant, anti-foaming agent, humectants, acidic agent, basic agent.

Clavulanic acid and its derivatives (for example potassium clavulanate) are very sensitive to humidity. For this reason, in formulations of the present invention potassium clavulanate can be used with a humidity absorbing agent, wherein ratio of potassium clavulanate to humidity absorbing agent is preferably in the ratio of 1 : 1.

As humidity absorbing agent one or more of agents which can be selected from the group comprising silica, colloidal silica, such as colloidal silica anhydrous, magnesium trisilicate, powdered cellulose, magnesium oxide, calcium silicate, Syloid®, starch, microcrystalline cellulose and talk. In the present invention preferably Syloid® or microcrystalline cellulose is used.

Binder used in the effervescent formulation in accordance with the present invention can be selected from, but not limited with, potato starch, wheat starch, corn starch, microcrystalline cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, hypromellose and polyvinyl pyrrolidone (povidone). Preferably, povidone is used. Lubricant used in the effervescent formulation in accordance with the present invention can be selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, sodium benzoate. Preferably, PEG 6000 is used. Sweetener and/or taste regulator that can be used in effervescent formulations of the present invention can be selected from a group comprising acesulfame, aspartame, dextrose, fructose, xylitol, saccharine, sucralose, saccharin, saccharin sodium, lactitol, maltitol, maltose, sorbitol, sodium cyclamate, sucrose and or a combination thereof. Preferably, aspartam is used.

Flavoring agents used in the present invention can be selected from a group comprising banana flavor, strawberry flavor, lemon flavor, orange flavor, peach flavor, vanilla flavor or similar natural fruits or might have the flavor of a natural herb.

Coloring agent used in the present invention can be selected from titanium dioxide pigments, indigo, carmine, beta carotene and iron oxide pigments. Preferably, beta carotene is used.

The effervescent formulation according to the present invention is prepared as a single pharmaceutical composition comprising the combination of two active agents.

In single dose of the formulations according to present invention; approximately 50 to 1300 mg of cefaclor and approximately 20 to 350 mg of potassium clavulanate are used.

In formulations of the present invention, ratio of cefaclor and potassium clavulanate is in the range of 1 :0.01 to 1 :10 by weight. Although potassium clavulanate is the most stable form of clavulanic acid, it is unstable against humidity. For this reason, formulations comprising clavulanic acid derivatives such as potassium clavulanate should be prepared under dry conditions, preferably at 0.5% of relative humidity and at a temperature of at least 20 °C. If applicable the components of the formulation may be dried beforehand. In another aspect, the present invention is related to the effervescent formulations comprising cefaclor in an amount of 10-60%, the mixture of potasium clavulanate: humidity absorbing agent (l :l)in an amount of 1-20%, effervescent couple in an amount of 15-55%, binder in an amount of 1-5 %, lubricant in an amount of 0.1-2 %, sweetener in an amount of 0.5-5 % by weight and at least one pharmaceutically acceptable excipient. Formulations of the present invention provide the use of the pharmaceutical formulation described above in the manufacture of a medicament for use in treatment of infections that are resistant to antibiotics. Said infectious diseases are; upper respiratory tract infections (acute otitis media, acute sinusitis, acute streptococci tonsilo pharangitis), urinary tract infections, commonly acquired pneumonia and skin and soft tissue infections.

The method given below which comprises spray granulation can be used for the preparation of effervescent formulations. Said method comprises the steps of; a) Preparation of the granulate by blending pharmaceutically active amount of effervescent couple and pharmaceutically acceptable excipients homogeneously, granulating the mixture by spraying with a sufficient amount of water and adding at least one pharmaceutically acceptable excipient to said granules and preparing the suitable granulate by sieving.

b) Preparation of the final mixture by adding cefaclor, potassium clavulanate: humidity absorbing agent (1 :1) mixture, lubricant and at least one pharmaceutically acceptable excipient to the granulate.

c) Preferably compressing the final mixture in the form of tablets.

Example seen below is given for demonstrating the invention. This example does not limit the scope of the invention and it is evaluated with respect to the description of the invention given above. EXAMPLE

1. Effervescent formulations

For preparation of granulate comprising cefaclor, effervescent couple and binder are mixed. For granulation, deionized water is added to the mixture and the mixture is blended until a granulate is obtained. The granules are then dried and sieved.

Cefaclor, pharmaceutically active amount of potassium clavulante:syloid mixture, lubricant, coloring agent and flavoring agent are then added to the obtained granulate, the final mixture is prepared and is compressed in the form of tablets.